MXPA05010629A - Vehiculo enmascarador del sabor para particulas de oxazolidinona recubiertas. - Google Patents

Vehiculo enmascarador del sabor para particulas de oxazolidinona recubiertas.

Info

Publication number
MXPA05010629A
MXPA05010629A MXPA05010629A MXPA05010629A MXPA05010629A MX PA05010629 A MXPA05010629 A MX PA05010629A MX PA05010629 A MXPA05010629 A MX PA05010629A MX PA05010629 A MXPA05010629 A MX PA05010629A MX PA05010629 A MXPA05010629 A MX PA05010629A
Authority
MX
Mexico
Prior art keywords
particles
oxazolidinone
coated
taste
same
Prior art date
Application number
MXPA05010629A
Other languages
English (en)
Inventor
Joseph P Reo
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA05010629A publication Critical patent/MXPA05010629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invencion esta dirigida a formulaciones secas de particulas de oxazolidinona recubiertas, tales como particulas de linezolid recubiertas, que, cuando estan suspendidas en una solucion acuosa, enmascaran el sabor de la oxazolidinona en el vehiculo de suspension resultante; especificamente, una mezcla de azucares en la formulacion, que comprende sorbitol y sacarosa, inhibe el transporte de masas de la oxazolidinona desde las particulas al vehiculo de suspension; se describen formulaciones secas de las particulas de oxazolidinona recubiertas, suspensiones de las mismas, y procedimientos de uso de las mismas para tratar o prevenir infecciones a partir de bacterias gram positivas.
MXPA05010629A 2003-03-31 2004-03-19 Vehiculo enmascarador del sabor para particulas de oxazolidinona recubiertas. MXPA05010629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45938203P 2003-03-31 2003-03-31
PCT/IB2004/000921 WO2004087108A1 (en) 2003-03-31 2004-03-19 Taste-masking vehicle for coated oxazolidinone particles

Publications (1)

Publication Number Publication Date
MXPA05010629A true MXPA05010629A (es) 2005-12-12

Family

ID=33131883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010629A MXPA05010629A (es) 2003-03-31 2004-03-19 Vehiculo enmascarador del sabor para particulas de oxazolidinona recubiertas.

Country Status (7)

Country Link
US (1) US20040191326A1 (es)
EP (1) EP1610764A1 (es)
JP (1) JP2006522089A (es)
BR (1) BRPI0408854A (es)
CA (1) CA2519869A1 (es)
MX (1) MXPA05010629A (es)
WO (1) WO2004087108A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
WO2010046933A2 (en) 2008-10-22 2010-04-29 Rubicon Research Private Limited Pharmaceutical compositions of taste-masked linezolid
MX2015013457A (es) 2013-03-21 2016-05-16 Eupraxia Pharmaceuticals USA LLC Composicion inyectable de liberación sostenida y metodo para su uso con el fin de tratar la inflamación en las articulaciones y el dolor asociado con ella.
MX2017003638A (es) * 2014-09-19 2017-11-08 Eupraxia Pharmaceuticals Inc Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
US11351124B2 (en) 2015-10-27 2022-06-07 Eupraxia Pharmaceuticals Inc. Sustained release of formulations of local anesthetics
CN105853351B (zh) * 2016-03-31 2019-02-22 重庆华邦制药有限公司 利奈唑胺口服混悬液及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4994260A (en) * 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
SE8605515D0 (sv) * 1986-12-22 1986-12-22 Astra Laekemedel Ab A liquid dosage form for oral administration of a pharmaceutically active substance
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
CA2121435C (en) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) * 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
AU3154895A (en) * 1994-08-01 1996-03-04 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
GB9601666D0 (en) * 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
GB2318511A (en) * 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
NZ505902A (en) * 1998-01-23 2003-08-29 Upjohn Co Oxazolidinone compounds useful as antimicrobial agents and combinatorial libraries
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation

Also Published As

Publication number Publication date
WO2004087108A1 (en) 2004-10-14
EP1610764A1 (en) 2006-01-04
JP2006522089A (ja) 2006-09-28
CA2519869A1 (en) 2004-10-14
BRPI0408854A (pt) 2006-04-04
US20040191326A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
TW200612971A (en) Method for preventing or treating respiratory infections and acute otitis media in infants
WO2008061243A3 (en) Respiratory syncytial virus-virus like particle (vlps)
CY1112004T1 (el) Αερολυματοποιημενος συνδυασμος φωσφομυκινης/αμινογλυκοζιτη για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
WO2007041156A3 (en) Antibiotic formulations, unit doses, kits, and methods
DE60327438D1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2009154304A3 (en) A pharmaceutical composition comprising rebamipide
WO2006050489A3 (en) Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
WO2005074990A3 (en) Methods of preventing and treating sars using low ph respiratory tract compositions
MXPA04012965A (es) Inhibidores virales.
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2004094386A8 (en) Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
WO2003026567A3 (en) Use of neuraminidase inhibitors to prevent flu associated bacterial infections
PT1057828E (pt) Suspensoes de trovafloxacina para administracao oral
MXPA05010629A (es) Vehiculo enmascarador del sabor para particulas de oxazolidinona recubiertas.
EP3939599A3 (en) Silicate containing compositions and methods of treatment
WO2005030109A3 (en) Regimen for the administration of rifamycin-class antibiotics
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
WO2005063281A3 (de) Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung
HK1048064A1 (en) Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
WO2002072581A3 (en) Pyrazolopyriadine derivatives
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten